MacroGenics, AbbVie drop partnered ADC programme

08 Mar 2024
firstwordpharma.com
ADCPhase 1AACRAcquisition
MacroGenics isn’t moving forward with an ADAM9-targeting antibody-drug conjugate (ADC) after lacklustre early data, and neither is partner AbbVie, who inherited the collaboration after its $10-billion acquisition of ImmunoGen.
However, Macrogenics isn’t giving up on the target; as part of its quarterly earnings Thursday, the company revealed an updated ADAM9 programme with a different cytotoxic payload.
MacroGenics originally partnered with ImmunoGen more than five years ago to equally share development of IMGC936, which delivers a maytansinoid payload, to treat various cancers. However, based on Phase I dose escalation and expansion data, the ADC didn’t reach pre-established safety and efficacy benchmarks.
In its earnings report, MacroGenics affirmed that ADAM9 “remains a promising target for delivery of an alternative cytotoxic payload” and unveiled MGC028, an ADC against ADAM9 that delivers a topoisomerase I inhibitor-based payload.
The company plans to present preclinical data for MGC028 at the American Association for Cancer Research (AACR) annual meeting in April. On a call with investors Thursday, CEO Scott Koenig gave a sneak-peek of the data, saying repeat dosing was well-tolerated in non-human primate toxicology studies. He added that the ADC “exhibited specific dose-dependent in vivo anti-tumour activity” in patient-derived cell and mouse models of cancers including gastric, lung, pancreatic, colorectal and head and neck cancers.
MacroGenics plans to submit a regulatory application with the FDA by year-end to begin clinical testing of MGC028. The company is also working on another topoisomerase I inhibitor-based ADC, dubbed MGC026, for which it recently began a Phase I study.
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Targets
Drugs
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.